Milestone Pharmaceuticals Inc.(MIST),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MIST Milestone Pharmaceuticals Inc.

Closed Good Friday 04-17 16:00:00 EDT

0.8889

+0.0719

+8.80%

盘后0.8710

-0.0179-2.01%

19:55 EDT

High0.9423	Low0.8350	Vol2.19M
Open0.8500	D1 Closing0.8170	Amplitude13.13%
Mkt Cap47.43M	Tradable Cap47.12M	Total Shares53.35M
T/O1.94M	T/O Rate4.14%	Tradable Shares53.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"MIST","market":"US","secType":"STK","nameCN":"Milestone Pharmaceuticals Inc.","latestPrice":0.8889,"timestamp":1744920000000,"preClose":0.817,"halted":0,"volume":2193095,"hourTrading":{"tag":"盘后","latestPrice":0.871,"preClose":0.8889,"latestTime":"19:55 EDT","volume":23997,"amount":21235.0343,"timestamp":1744934127026},"delay":0,"floatShares":53004500,"shares":53353984,"eps":-0.667393,"marketStatus":"Closed Good Friday","change":0.0719,"latestTime":"04-17 16:00:00 EDT","open":0.85,"high":0.9423,"low":0.835,"amount":1940744.1114205,"amplitude":0.131334,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.667393,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1557374400000,"exchange":"NASDAQ","adjPreClose":0.817,"preHourTrading":{"tag":"盘前","latestPrice":0.85,"preClose":0.817,"latestTime":"09:27 EDT","volume":101713,"amount":87282.0917869,"timestamp":1744896455909},"postHourTrading":{"tag":"盘后","latestPrice":0.871,"preClose":0.8889,"latestTime":"19:55 EDT","volume":23997,"amount":21235.0343,"timestamp":1744934127026},"volumeRatio":2.4076683277968365,"impliedVol":1.4619,"impliedVolPercentile":0.7131},"requestUrl":"/m/hq/s/MIST","defaultTab":"news","newsList":[{"id":"2524262431","title":"TD downgrades Milestone Pharmaceuticals, suspends target on Etripamil uncertainty","url":"https://stock-news.laohu8.com/highlight/detail?id=2524262431","media":"Investing.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524262431?lang=en_us&edition=full_marsco","pubTime":"2025-04-02 03:48","pubTimestamp":1743536928,"startTime":"0","endTime":"0","summary":"Investing.com --TD Securities downgraded Milestone Pharmaceuticals  to \"Hold\" and suspended its price target, citing regulatory uncertainty and commercialization challenges for its lead drug, etripamil, following a Complete Response Letter from the U.S. Food and Drug Administration.The FDA issued a Complete Response Letter for MIST’s etripamil New Drug Application for paroxysmal supraventricular tachycardia , citing chemistry, manufacturing, and controls issues. While no safety or efficacy concerns were raised, the agency requested additional data on nitrosamine impurities based on new draft guidance published in September 2024, months after MIST had resubmitted its New Drug Application . The FDA also flagged the need for an inspection at a third-party facility performing release testing, which changed ownership during the New Drug Application review.TD expressed concerns over etripamil’s commercial viability, noting Milestone Pharmaceuticals' limited capital reserves. The company had ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/td-downgrades-milestone-pharmaceuticals-suspends-194848951.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TD","MIST"],"gpt_icon":0},{"id":"2524949144","title":"Milestone Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2524949144","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524949144?lang=en_us&edition=full_marsco","pubTime":"2025-04-02 00:43","pubTimestamp":1743525780,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MIST/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 01, 2025 12:43 ET (16:43 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIST"],"gpt_icon":0},{"id":"2524146506","title":"Milestone Pharmaceuticals Inc : H.c. Wainwright Cuts Target Price to $10 From $25","url":"https://stock-news.laohu8.com/highlight/detail?id=2524146506","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524146506?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 23:33","pubTimestamp":1743521611,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250401:nFWN3QF16X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MIST"],"gpt_icon":0},{"id":"2524781143","title":"BUZZ-Milestone Pharma falls after TD Cowen downgrades to \"hold\", removes PT","url":"https://stock-news.laohu8.com/highlight/detail?id=2524781143","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524781143?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 23:06","pubTimestamp":1743520012,"startTime":"0","endTime":"0","summary":"BUZZ-Milestone Pharma falls after TD Cowen downgrades to \"hold\", removes PT** Shares of drug developer Milestone Pharmaceuticals MIST.O fall 8% to 73 cents, extending decline to third day. ** Brokerage TD Cowen downgrades MIST to \"hold\" from \"buy\", removes PT. ** Cites etripamil's regulatory and commercial timing uncertainty. ** \"The lack of clarity on regulatory timelines puts additional strain on the company's limited capital,\" says brokerage. ** MIST shares fell ~61% on Friday after the U.S. FDA declined to approve its nasal spray, Cardamyst, to treat a type of heart condition. ** Including session moves, MIST stock down ~69% YTD compared to ~5% decline in the S&P 500 index .SPX","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250401:nL6N3QF0PA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIST"],"gpt_icon":0},{"id":"2524143327","title":"HC Wainwright Adjusts Price Target on Milestone Pharmaceuticals to $10 From $25, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2524143327","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524143327?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 22:55","pubTimestamp":1743519344,"startTime":"0","endTime":"0","summary":"Milestone Pharmaceuticals (MIST) has an average rating of overweight and mean price target of $4.75, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic researc","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MIST"],"gpt_icon":0},{"id":"2524603115","title":"Milestone Pharmaceuticals Inc : TD Cowen Cuts to Hold From Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2524603115","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524603115?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 20:41","pubTimestamp":1743511274,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250401:nFWN3QF15O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MIST","BK4007"],"gpt_icon":0},{"id":"2524186197","title":"TD Cowen Downgrades Milestone Pharmaceuticals to Hold From Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2524186197","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524186197?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 19:42","pubTimestamp":1743507744,"startTime":"0","endTime":"0","summary":"Milestone Pharmaceuticals (MIST) has an average rating of overweight and mean price target of $4.75, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic researc","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["COWN","MIST","TD"],"gpt_icon":0},{"id":"2523686722","title":"BUZZ-U.S. STOCKS ON THE MOVE-GameStop, Oxford Industries, Wolfspeed","url":"https://stock-news.laohu8.com/highlight/detail?id=2523686722","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523686722?lang=en_us&edition=full_marsco","pubTime":"2025-03-29 01:47","pubTimestamp":1743184057,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-GameStop, Oxford Industries, WolfspeedEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newslet","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nL6N3QB0IK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GHLD","3NVD.UK","NVD3.UK","PTCT","NVDU","AGX","MIST","MRK","LGMK","NVDD","BEAM","GME","NVD2.UK","NVDY","NVD","OXM","LUV","CVAC","DTC","SGHC","CPT","X","NVDS.UK","2NVD.UK","NEM","ENPH","AU","LXRX","ON","WRB","NVIW.SI","AIR","ECX","LDOS","SNVD.UK","NVDX","WOLF","NVDS","XPO","STSS"],"gpt_icon":1},{"id":"2523268671","title":"Milestone Pharmaceuticals Price Target Maintained With a $25.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2523268671","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523268671?lang=en_us&edition=full_marsco","pubTime":"2025-03-29 01:47","pubTimestamp":1743184020,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MIST/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 28, 2025 13:47 ET (17:47 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIST"],"gpt_icon":0},{"id":"2523500809","title":"Dow Tumbles Over 500 Points; Abacus Global Management Shares Spike Higher","url":"https://stock-news.laohu8.com/highlight/detail?id=2523500809","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523500809?lang=en_us&edition=full_marsco","pubTime":"2025-03-29 00:14","pubTimestamp":1743178491,"startTime":"0","endTime":"0","summary":" ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/25/03/44540623/dow-tumbles-over-500-points-abacus-global-management-shares-spike-higher","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QLD","USAW.SI","PSQ","XTIA","USJW.SI","IE00B19Z4B17.USD","TSYW.SI","MIST","PRTG","ABL","BK4572","PCOM","NQmain",".IXIC","IE00B7SZL793.SGD","AIR","BK4139","BK4122","BK4173","MNQmain","TQQQ","BK4187","NVIW.SI","BK4134","BK4007","IE0031619046.USD","SQQQ","QID","IE00B66KJ199.SGD","DBVT"],"gpt_icon":1},{"id":"2522501719","title":"Piper Sandler Adjusts Price Target on Milestone Pharmaceuticals to $4 From $5, Maintains Overweight Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2522501719","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522501719?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 23:13","pubTimestamp":1743174796,"startTime":"0","endTime":"0","summary":"Milestone Pharmaceuticals (MIST) has an average rating of buy and mean price target of $10, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from ma","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MIST"],"gpt_icon":0},{"id":"2522577404","title":"Milestone Pharmaceuticals Shares Down 64.7% After FDA Declines to Approve Co's Heart Rhythm Nasal Spray","url":"https://stock-news.laohu8.com/highlight/detail?id=2522577404","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522577404?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 21:34","pubTimestamp":1743168863,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nFWN3QB0L6:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MIST","BK4007"],"gpt_icon":0},{"id":"2522578087","title":"BRIEF-FDA Issues Complete Response Letter For Etripamil For PSVT","url":"https://stock-news.laohu8.com/highlight/detail?id=2522578087","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522578087?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 19:53","pubTimestamp":1743162834,"startTime":"0","endTime":"0","summary":"BRIEF-FDA Issues Complete Response Letter For Etripamil For PSVTMarch 28 (Reuters) - Milestone Pharmaceuticals Inc MIST.O:FDA ISSUES COMPLETE RESPONSE LETTER FOR ETRIPAMIL FOR PSVTMILESTONE PHARMACEUT","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nTUA2SXRZ8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIST","BK4007"],"gpt_icon":1},{"id":"2522157850","title":"BUZZ-Milestone Pharma slumps after FDA declines to approve heart rhythm nasal spray","url":"https://stock-news.laohu8.com/highlight/detail?id=2522157850","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522157850?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 19:46","pubTimestamp":1743162374,"startTime":"0","endTime":"0","summary":"BUZZ-Milestone Pharma slumps after FDA declines to approve heart rhythm nasal spray** Shares of drug developer Milestone Pharmaceuticals MIST.O fall 62.7% to 84 cents premarket** US FDA declined to approve MIST's nasal spray, Cardamyst, to treat a type of heart condition, company says** FDA raised no concerns about clinical safety or efficacy, but highlighted two key chemistry, manufacturing and controls issues - MIST** Issues include needing additional information on nitrosamine impurities, cancer-causing compounds formed during manufacturing and an inspection of a testing facility** Shares up 25% in the last 12 months, as of last close  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nL3N3QB0W1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MIST"],"gpt_icon":0},{"id":"2522520175","title":"Milestone Pharmaceuticals Shares Down 60% Premarket After FDA Declines to Approve Co's Heart Rhythm Nasal Spray","url":"https://stock-news.laohu8.com/highlight/detail?id=2522520175","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522520175?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 19:32","pubTimestamp":1743161554,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nFWN3QB0K7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MIST"],"gpt_icon":0},{"id":"2522527170","title":"FDA Rejects Milestone Pharmaceuticals' Etripamil Nasal Spray","url":"https://stock-news.laohu8.com/highlight/detail?id=2522527170","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522527170?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 19:20","pubTimestamp":1743160800,"startTime":"0","endTime":"0","summary":"The Food and Drug Administration has turned away a proposed nasal spray from Milestone Pharmaceuticals to treat a type of irregular heartbeat over concerns about how the drug is manufactured.Milestone said Friday that the FDA has issued a so-called complete response letter for the drug, etripamil, indicating the agency won't approve the application in its current form and called for additional studies.The Montreal biopharmaceutical company, which was seeking FDA approval of etripamil for the conversion of acute episodes of paroxysmal supraventricular tachycardia, or PSVT, to sinus rhythm in adults, said the agency didn't raise any concerns about the drug's clinical safety or efficacy data, but flagged two key chemistry, manufacturing and controls issues to be addressed.Milestone said the FDA requested additional information on nitrosamine impurities based on new draft guidance issued after the company filed its new-drug application for etripamil.The company said the FDA is also requiri","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"FDA Rejects Milestone Pharmaceuticals' Etripamil Nasal Spray","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MIST"],"gpt_icon":1},{"id":"2522522661","title":"US FDA declines to approve Milestone Pharma's heart rhythm nasal spray","url":"https://stock-news.laohu8.com/highlight/detail?id=2522522661","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522522661?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 19:03","pubTimestamp":1743159785,"startTime":"0","endTime":"0","summary":"US FDA declines to approve Milestone Pharma's heart rhythm nasal sprayMarch 28  - The U.S. Food and Drug Administration has declined to approve Milestone Pharmaceuticals' MIST.O nasal spray to treat a type of heart condition, the company said on Friday.      ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nL3N3QB0TL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MIST"],"gpt_icon":0},{"id":"2522952409","title":"Milestone Pharmaceuticals Inc - Inspection Required at Facility Performing Etripamil Release Testing","url":"https://stock-news.laohu8.com/highlight/detail?id=2522952409","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522952409?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 19:00","pubTimestamp":1743159600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nTUA2SXRZ8:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MIST"],"gpt_icon":0},{"id":"2522752408","title":"Milestone Pharmaceuticals Inc - FDA Raises No Concerns on Etripamil Clinical Safety or Efficacy","url":"https://stock-news.laohu8.com/highlight/detail?id=2522752408","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522752408?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 19:00","pubTimestamp":1743159600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nTUA2SXRZ8:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MIST"],"gpt_icon":0},{"id":"2522524060","title":"Milestone Pharmaceuticals Inc - Company to Submit Additional Info on Nitrosamine Impurities","url":"https://stock-news.laohu8.com/highlight/detail?id=2522524060","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522524060?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 19:00","pubTimestamp":1743159600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nTUA2SXRZ8:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MIST","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.milestonepharma.com","stockEarnings":[{"period":"1week","weight":0.1852},{"period":"1month","weight":-0.6265},{"period":"3month","weight":-0.5511},{"period":"6month","weight":-0.4034},{"period":"1year","weight":-0.4921},{"period":"ytd","weight":-0.6233}],"compareEarnings":[{"period":"1week","weight":0.0035},{"period":"1month","weight":-0.0617},{"period":"3month","weight":-0.1191},{"period":"6month","weight":-0.0995},{"period":"1year","weight":0.0517},{"period":"ytd","weight":-0.1018}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. Milestone Pharmaceuticals Inc. has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.042562},{"month":2,"riseRate":0.166667,"avgChangeRate":-0.118335},{"month":3,"riseRate":0.5,"avgChangeRate":-0.166289},{"month":4,"riseRate":0.666667,"avgChangeRate":0.106313},{"month":5,"riseRate":0.6,"avgChangeRate":-0.015932},{"month":6,"riseRate":0.5,"avgChangeRate":0.019419},{"month":7,"riseRate":0.833333,"avgChangeRate":0.228377},{"month":8,"riseRate":0.5,"avgChangeRate":0.054646},{"month":9,"riseRate":0.5,"avgChangeRate":-0.000002},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.145809},{"month":11,"riseRate":0.5,"avgChangeRate":0.111894},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.060182}],"exchange":"NASDAQ","name":"Milestone Pharmaceuticals Inc.","nameEN":"Milestone Pharmaceuticals Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Milestone Pharmaceuticals Inc.(MIST),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Milestone Pharmaceuticals Inc.(MIST) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Milestone Pharmaceuticals Inc.,MIST,Milestone Pharmaceuticals Inc.股票,Milestone Pharmaceuticals Inc.股票老虎,Milestone Pharmaceuticals Inc.股票老虎国际,Milestone Pharmaceuticals Inc.行情,Milestone Pharmaceuticals Inc.股票行情,Milestone Pharmaceuticals Inc.股价,Milestone Pharmaceuticals Inc.股市,Milestone Pharmaceuticals Inc.股票价格,Milestone Pharmaceuticals Inc.股票交易,Milestone Pharmaceuticals Inc.股票购买,Milestone Pharmaceuticals Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Milestone Pharmaceuticals Inc.(MIST),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Milestone Pharmaceuticals Inc.(MIST) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction